Company intelligence / Profile preview

Solian

Zurich, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

Solianis Monitoring AG was a Swiss medical technology company focused on developing non-invasive continuous glucose monitoring (CGM) systems for patients with diabetes. The company's core technology utilized a multisensor approach to track glucose levels through the skin without the need for blood samples or interstitial fluid extraction. Their lead product candidate was a wearable device designed to provide real-time glucose data to improve glycemic control. In 2010, the company's assets and technology were acquired by Biovotion AG, which continued the development of wearable physiological monitoring solutions.

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Solian.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solian.

Explore the full profile